Wegovy Pill Gains UK Approval, Boosts Novo's Market

Britain’s medicines regulator licensed Novo Nordisk’s (NVO) oral Wegovy weight-loss pill on Thursday, making the U.K. the third jurisdiction to approve the tablet form and reinforcing the Danish drugmaker’s bid to defend leadership in the fast-moving obesity market.

For investors, the U.K. clearance is a meaningful commercial catalyst: it adds tens of millions of potential patients to the addressable market for a pill format that Novo Nordisk said already delivers roughly 17% average weight loss under trial conditions – performance that analysts say narrows the efficacy gap with rival injectable therapies. ¹

Key Takeaways

U.K. becomes the third market to approve Wegovy’s oral pill form.
Oral semaglutide 25 mg showed ~17% weight loss in OASIS 4 trial.
Novo Nordisk positions pill to reclaim obesity-market leadership.

Market Reaction & Context

The U.K. approval arrives roughly six months after the U.S. Food and Drug Administration cleared the Wegovy pill on December 22, 2025, with a broad U.S. commercial rollout following in early January 2026. ² Novo Nordisk shares (NVO) have faced pressure over the past year as Eli Lilly’s tirzepatide-based Zepbound gained injectable market share; the pill format, which the company describes as the first oral GLP-1 receptor agonist for obesity, is widely regarded by sell-side analysts as the most important near-term lever for reversing that trend.

The British approval positions the Wegovy pill against a U.K. obesity drug market that already includes Novo’s own injectable Wegovy and Lilly’s Mounjaro – meaning the oral entrant competes partly with its own franchise while targeting the large cohort of patients resistant to self-injection. ³

Detailed Analysis

The core clinical case rests on the OASIS 4 phase 3b trial, a 64-week study in 307 adults with obesity or overweight plus at least one comorbidity. Participants taking oral semaglutide 25 mg once daily alongside a reduced-calorie diet and exercise achieved a mean weight loss of 16.6% when treatment was adhered to, versus roughly 2.7% for placebo. ²

On a treatment-policy basis – which captures outcomes regardless of whether patients stayed on the drug – weight loss averaged 13.6%, still a clinically meaningful result. Novo Nordisk said the safety profile of the pill was consistent with that seen in prior semaglutide trials, with nausea, diarrhea, and vomiting the most common adverse reactions. ²

The oral format carries a distinct commercial logic beyond convenience: it removes the cold-chain and needle-phobia barriers that have historically capped GLP-1 penetration, particularly in primary-care settings and lower-income markets. In the U.S., Novo Nordisk priced the starting 1.5 mg dose at $149 per month for self-pay patients, with commercially insured patients eligible for as little as $25 per month. ¹

Novo Nordisk said it submitted oral semaglutide 25 mg to the European Medicines Agency and other regulators during the second half of 2025, suggesting additional approvals could follow within 12 to 18 months if review timelines are standard. ²

Outlook & Management Comment

Novo Nordisk chief executive Mike Doustdar struck a confident tone at the time of the FDA clearance, a sentiment the company has reiterated as international approvals accumulate.

“The pill is here. With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection,” Doustdar said. “No other current oral GLP-1 treatment can match the weight loss delivered by the Wegovy pill.” ²

The U.K. green light is the third regulatory licence for the tablet, following the U.S. and at least one other authority, and it underscores how quickly Novo Nordisk is converting clinical data into commercial approvals across major markets. Whether EMA clearance, expected to follow, can meaningfully shift the competitive dynamic with Lilly’s dual-mechanism tirzepatide will be among the most closely watched catalysts for NVO shares in the second half of 2026. ³

Conclusion

The U.K. approval of the Wegovy pill gives Novo Nordisk a third platform from which to market the first oral GLP-1 obesity therapy, broadening revenue diversification and reducing reliance on the injectable franchise that has faced intensifying competition. Deal-focused investors should monitor EMA review progress, NHS pricing negotiations, and U.K. prescription-volume data as early indicators of the pill’s real-world commercial traction.

Not investment advice. For informational purposes only.